OR WAIT null SECS
November 21, 2022
Tzield (teplizumab-mzwv) injection is the first FDA-approved therapy designed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older.
Initially rejected in July 2021, XPHOZAH (tenapanor) won recommendations as both a monotherapy and combination treatment from FDA’s CRDAC meeting.
Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.
Element has opened a new 7500-ft3 facility that will be used to evaluate aerosolized product efficacy for reducing airborne organisms and viral particles.
November 17, 2022
CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.
November 16, 2022
The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.
Indivior’s acquisition of Opiant grants them access to the company’s portfolio of investigational opioid overdose reversal agent, OPNT003.
November 14, 2022
The new facility will allow ReiThera to consolidate its competitive position as a leading CDMO specialized in viral vector production.
Avantor is continuing its investment to support the biopharma market with the opening of its new distribution center in Dublin, Ireland.
Salipro Biotech has entered into a collaboration and license agreement with Sanofi to advance discovery programs.